Alnylam Pharmaceuticals, Inc. (ALNY) — the Cambridge, Massachusetts-based leader in RNA interference (RNAi) therapeutics — has experienced one of the more volatile stretches in its recent history. After peaking near $495 in late 2025, the stock collapsed below $200 following a second-quarter 2026 guidance cut, then recovered to roughly $265. Against that backdrop, the question on many investors' minds is straightforward: can ALNY claw its way back to $400?
$400 is significant for three reasons. First, it is a round-number psychological milestone. Second, it sits almost exactly at the consensus analyst price target, giving it real institutional credibility. Third, ALNY has already traded well above this level within the past year, which means $400 is not an untested fantasy — it is a recovery zone rather than uncharted territory.
Alnylam has evolved from a research-stage biotech into a profitable commercial company with six marketed medicines, including AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO, and partnered products such as Leqvio (with Novartis) and Qfitlia (with Sanofi). Revenue climbed 65% to about $3.7 billion in 2025, and the company turned GAAP profitable.
The turbulence began in July 2026, when second-quarter results — despite 67% revenue growth to $1.29 billion and a return to profitability — were overshadowed by a guidance reduction. Management lowered its 2026 TTR revenue outlook by roughly $200 million at the midpoint, citing slower-than-expected normalization of second-line AMVUTTRA demand after an initial surge of pent-up patients. Shares fell about 28% in a single session and briefly touched $197.81, a 52-week low, before rebounding to the mid-$260s.
AMVUTTRA remains the central engine. Approved for ATTR-CM in May 2025, it is the only therapy approved for both the cardiomyopathy and polyneuropathy forms of ATTR amyloidosis, and it has been capturing a majority of new patient starts among experienced prescribers. The franchise crossed $1 billion in a single quarter, a milestone management achieved far faster than rivals did historically.
Beyond the current franchise, Alnylam's pipeline offers longer-dated optionality. Nucresiran, a next-generation TTR silencer targeting a potential 2030 launch, and zilebesiran, a blood-pressure therapy being developed with Roche, anchor an "Alnylam 2030" strategy aimed at sustained revenue growth and expanding margins. A $3.3 billion cash position provides runway to fund these programs.
The primary risk is that the ATTR-CM launch does not re-accelerate as hoped. Competition is intensifying: Pfizer's (PFE) Vyndamax, BridgeBio's (BBIO) Attruby, and Ionis Pharmaceuticals' (IONS) eplontersen all compete in overlapping ATTR markets. If second-line demand growth stays muted, further guidance adjustments could pressure the stock.
Valuation and sentiment add friction. Even after the selloff, ALNY trades at a premium to many biotech peers, and the post-guidance period has brought analyst target cuts and shareholder scrutiny. A rich multiple means the stock needs earnings and revenue momentum to justify sustained gains, not merely stabilization.
Wall Street remains broadly constructive but more divided than before. Consensus price targets cluster in the $394–$412 range, implying meaningful upside from current levels. Following the guidance cut, however, several firms trimmed targets — Oppenheimer and RBC Capital moved to roughly $350, Stifel to about $318, while Barclays held a higher figure near $450. This dispersion underscores a key point: the path to $400 is credible, but it is no longer the near-unanimous expectation it was before the July reset.
From a technical perspective, $400 functions as both a psychological resistance level and a former support zone from when the stock traded above it in 2025. A sustained move toward that level would likely require reclaiming intermediate thresholds and confirming demand above the current mid-$260s consolidation. The $197.81 low stands as the critical downside reference, while the $495.55 high frames the upper boundary of the past year's range.
For traders looking to track momentum shifts across thousands of instruments, Tickeron's AI Daily Buy/Sell Signals offers an AI-driven approach to market monitoring. The tool continuously analyzes stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-powered analysis. Investors can use these signals to surface new opportunities, monitor existing positions, and identify evolving trends more efficiently than manual scanning allows. Traders interested in a data-driven edge may find the AI Daily Buy/Sell Signals a useful addition to their research workflow.
Reaching $400 is a realistic but by no means guaranteed outcome for ALNY. The case for the move rests on AMVUTTRA's demonstrated clinical and commercial momentum, a deep pipeline, and a robust cash position — all of which support a recovery if the ATTR-CM launch regains its footing. The case against hinges on the guidance reset, intensifying competition, and a premium valuation that leaves little room for further disappointment. Investors should monitor AMVUTTRA prescription trends, any updates to 2026 guidance, and progress on nucresiran and zilebesiran, as these factors will ultimately determine whether the path back to $400 can be sustained.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ALNY has been loosely correlated with PHAT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ALNY jumps, then PHAT could also see price increases.
| Ticker / NAME | Correlation To ALNY | 1D Price Change % | ||
|---|---|---|---|---|
| ALNY | 100% | -2.42% | ||
| PHAT - ALNY | 43% Loosely correlated | -3.48% | ||
| UTHR - ALNY | 35% Loosely correlated | -0.53% | ||
| AXON - ALNY | 35% Loosely correlated | -1.27% | ||
| MDGL - ALNY | 34% Loosely correlated | -0.54% | ||
| BCRX - ALNY | 33% Loosely correlated | -0.23% | ||
More | ||||